A new lease on life for an HIV-neutralizing antibody class and vaccine target.
作者信息
Burton Dennis R
机构信息
Department of Immunology and Microbiology, IAVI Neutralizing Antibody Center, Consortium for HIV/AIDS Vaccine Development, The Scripps Research Institute, La Jolla, CA 92037;
Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology, and Harvard University, Cambridge, MA 02139.
出版信息
Proc Natl Acad Sci U S A. 2021 Feb 16;118(7). doi: 10.1073/pnas.2026390118.
Abstract
摘要
相似文献
1
A new lease on life for an HIV-neutralizing antibody class and vaccine target.一类HIV中和抗体及疫苗靶点迎来了新的生机。
Proc Natl Acad Sci U S A. 2021 Feb 16;118(7). doi: 10.1073/pnas.2026390118.
2
Toward an antibody-based HIV-1 vaccine.朝着基于抗体的 HIV-1 疫苗努力。
Annu Rev Med. 2010;61:135-52. doi: 10.1146/annurev.med.60.042507.164323.
3
In vivo protection by broadly neutralizing HIV antibodies.HIV 广谱中和抗体的体内保护作用。
Trends Microbiol. 2014 Oct;22(10):550-1. doi: 10.1016/j.tim.2014.08.006. Epub 2014 Aug 26.
4
HIV vaccine development--improving on natural immunity.HIV疫苗研发——改进天然免疫
N Engl J Med. 2011 Sep 8;365(10):873-5. doi: 10.1056/NEJMp1107621.
5
HIV-1 envelope gp41 broadly neutralizing antibodies: hurdles for vaccine development.HIV-1包膜糖蛋白gp41广泛中和抗体：疫苗开发的障碍
PLoS Pathog. 2014 May 22;10(5):e1004073. doi: 10.1371/journal.ppat.1004073. eCollection 2014 May.
6
Neutralizing antibodies against HIV-1: can we elicit them with vaccines and how much do we need?抗 HIV-1 的中和抗体：我们能否用疫苗诱导产生，需要多少？
Curr Opin HIV AIDS. 2009 Sep;4(5):347-51. doi: 10.1097/COH.0b013e32832f4a4d.
7
HIV Vaccines: One Step Closer.HIV 疫苗：更近一步。
Trends Mol Med. 2017 Jan;23(1):1-3. doi: 10.1016/j.molmed.2016.10.006. Epub 2016 Nov 23.
8
HIV. The modern era of HIV-1 vaccine development.人类免疫缺陷病毒。HIV-1疫苗研发的现代时代。
Science. 2015 Jul 10;349(6244):139-40. doi: 10.1126/science.aac7800.
9
Broadly neutralizing antibodies and the search for an HIV-1 vaccine: the end of the beginning.广谱中和抗体与 HIV-1 疫苗的研发：万里长征第一步。
Nat Rev Immunol. 2013 Sep;13(9):693-701. doi: 10.1038/nri3516.
10
HIV Vaccine efficacy trial: glimmers of hope and the potential role of antibody-dependent cellular cytotoxicity.HIV疫苗效力试验：希望之光与抗体依赖性细胞毒性的潜在作用
Hum Vaccin. 2011 Apr;7(4):466-73. doi: 10.4161/hv.7.4.14123. Epub 2011 Apr 1.
引用本文的文献
1
Utilizing Machine Learning to Improve Neutralization Potency of an HIV-1 Antibody Targeting the gp41 N-Heptad Repeat.利用机器学习提高靶向gp41 N-七肽重复序列的HIV-1抗体的中和效力。
ACS Chem Biol. 2025 Jul 18;20(7):1470-1480. doi: 10.1021/acschembio.5c00035. Epub 2025 Jun 20.
2
HIV-1 prehairpin intermediate inhibitors show efficacy independent of neutralization tier.HIV-1 发夹前中间体抑制剂的疗效不依赖中和作用。
Proc Natl Acad Sci U S A. 2023 Feb 21;120(8):e2215792120. doi: 10.1073/pnas.2215792120. Epub 2023 Feb 16.
3
A human antibody reveals a conserved site on beta-coronavirus spike proteins and confers protection against SARS-CoV-2 infection.一种人类抗体揭示了β冠状病毒刺突蛋白上的一个保守位点，并赋予对SARS-CoV-2感染的保护作用。
Sci Transl Med. 2022 Mar 23;14(637):eabi9215. doi: 10.1126/scitranslmed.abi9215.
4
A Derivative of the D5 Monoclonal Antibody That Targets the gp41 N-Heptad Repeat of HIV-1 with Broad Tier-2-Neutralizing Activity.一种针对 HIV-1 gp41 N-七肽重复序列的 D5 单克隆抗体衍生物，具有广泛的 Tier-2 中和活性。
J Virol. 2021 Jul 12;95(15):e0235020. doi: 10.1128/JVI.02350-20.
5
A human antibody reveals a conserved site on beta-coronavirus spike proteins and confers protection against SARS-CoV-2 infection.一种人类抗体揭示了β冠状病毒刺突蛋白上的一个保守位点，并赋予对SARS-CoV-2感染的保护作用。
bioRxiv. 2022 Jan 21:2021.03.30.437769. doi: 10.1101/2021.03.30.437769.
本文引用的文献
1
A Derivative of the D5 Monoclonal Antibody That Targets the gp41 N-Heptad Repeat of HIV-1 with Broad Tier-2-Neutralizing Activity.一种针对 HIV-1 gp41 N-七肽重复序列的 D5 单克隆抗体衍生物，具有广泛的 Tier-2 中和活性。
J Virol. 2021 Jul 12;95(15):e0235020. doi: 10.1128/JVI.02350-20.
2
The high-affinity immunoglobulin receptor FcγRI potentiates HIV-1 neutralization via antibodies against the gp41 N-heptad repeat.高亲和力免疫球蛋白受体 FcγRI 通过针对 gp41 N-七肽重复序列的抗体增强 HIV-1 中和作用。
Proc Natl Acad Sci U S A. 2021 Jan 19;118(3). doi: 10.1073/pnas.2018027118.
3
A Meta-analysis of Passive Immunization Studies Shows that Serum-Neutralizing Antibody Titer Associates with Protection against SHIV Challenge.一项针对被动免疫研究的荟萃分析表明，血清中和抗体滴度与预防 SHIV 挑战相关。
Cell Host Microbe. 2019 Sep 11;26(3):336-346.e3. doi: 10.1016/j.chom.2019.08.014.
4
Antibody barriers to going viral.抗体对病毒传播的阻碍。
J Exp Med. 2019 Oct 7;216(10):2226-2228. doi: 10.1084/jem.20191099. Epub 2019 Aug 23.
5
Passive and active antibody studies in primates to inform HIV vaccines.灵长类动物的被动和主动抗体研究，为 HIV 疫苗提供信息。
Expert Rev Vaccines. 2018 Feb;17(2):127-144. doi: 10.1080/14760584.2018.1425619. Epub 2018 Jan 19.
6
Engineered Bispecific Antibodies with Exquisite HIV-1-Neutralizing Activity.具有卓越HIV-1中和活性的工程化双特异性抗体。
Cell. 2016 Jun 16;165(7):1621-1631. doi: 10.1016/j.cell.2016.05.024.
7
Neutralization of Virus Infectivity by Antibodies: Old Problems in New Perspectives.抗体对病毒感染性的中和作用：新视角下的老问题
Adv Biol. 2014;2014. doi: 10.1155/2014/157895. Epub 2014 Sep 9.
8
Neutralizing antibodies to HIV-1 envelope protect more effectively in vivo than those to the CD4 receptor.针对HIV-1包膜的中和抗体在体内的保护作用比针对CD4受体的中和抗体更有效。
Sci Transl Med. 2014 Jul 2;6(243):243ra88. doi: 10.1126/scitranslmed.3008992.
9
Antibody-DEPENDENT, FcγRI-mediated neutralization of HIV-1 in TZM-bl cells occurs independently of phagocytosis.抗体依赖性、FcγRI 介导的 TZM-bl 细胞中 HIV-1 的中和作用不依赖于吞噬作用。
J Virol. 2013 May;87(9):5287-90. doi: 10.1128/JVI.00278-13. Epub 2013 Feb 13.
10
Broadly neutralizing monoclonal antibodies 2F5 and 4E10 directed against the human immunodeficiency virus type 1 gp41 membrane-proximal external region protect against mucosal challenge by simian-human immunodeficiency virus SHIVBa-L.广谱中和单克隆抗体 2F5 和 4E10 针对人类免疫缺陷病毒 1 型 gp41 膜近端外部区域，可预防猴免疫缺陷病毒 SHIVBa-L 的粘膜攻击。
J Virol. 2010 Feb;84(3):1302-13. doi: 10.1128/JVI.01272-09. Epub 2009 Nov 11.
Zotero 插件